MTVA
MetaVia Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.79
−2.99%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 10.0K | 19.0K | 24.0K | 7.0K | 28.0K |
| Gross Profit | (10.0K) | (19.0K) | (24.0K) | (7.0K) | (28.0K) |
| Operating Expenses | |||||
| R&D Expense | 7.7M | 6.8M | 21.5M | 9.2M | 2.8M |
| SG&A Expense | 7.2M | 6.9M | 7.3M | 6.7M | 8.6M |
| General & Admin Expense | 3.5M | — | 7.3M | 6.7M | 8.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | 24.0K | — | 8.2M |
| Total Operating Expenses | 14.9M | 13.7M | 28.8M | 15.9M | 19.6M |
| Cost and Expenses | 14.9M | 13.7M | 28.8M | 15.9M | 19.6M |
| Operating Income (EBIT) | (14.9M) | (13.7M) | (28.8M) | (15.9M) | (19.6M) |
| Non-Operating | |||||
| Interest Income | 394.0K | 510.0K | 920.0K | 461.0K | — |
| Interest Expense | — | — | — | — | 2.2M |
| Net Interest Income | 394.0K | 510.0K | 920.0K | 461.0K | (2.2M) |
| Other Non-Op Income/Expense | 485.0K | 735.0K | 1.2M | 3.4M | 5.7M |
| Non-Operating Income (excl Interest) | (416.0K) | (735.0K) | (1.2M) | (3.4M) | (7.9M) |
| EBT (Pre-Tax Income) | (14.4M) | (13.0M) | (27.6M) | (12.5M) | (14.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (14.4M) | (13.0M) | (27.6M) | (12.5M) | (14.0M) |
| Earnings from Cont. Ops | (14.4M) | (13.0M) | (27.6M) | (12.5M) | (14.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (14.4M) | (13.0M) | (27.6M) | (12.5M) | (14.0M) |
| Per Share | |||||
| Basic EPS | ($4.07) | ($7.35) | ($39.16) | ($27.06) | ($477.84) |
| Diluted EPS | ($4.07) | ($7.35) | ($39.16) | ($27.06) | ($477.84) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 5.9M | 1.8M | 705193 | 461009 | 29246 |
| Diluted Shares Outstanding | 5.9M | 1.8M | 705193 | 461009 | 29246 |
| Profitability Metrics | |||||
| EBITDA | (14.5M) | (13.0M) | (27.6M) | (12.5M) | (11.8M) |
| D&A | 19.0K | 19.0K | 24.0K | 6.0K | 20.0K |
| EBIT | (14.5M) | (13.0M) | (27.6M) | (12.5M) | (11.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026